People · Operator
Named in public records as an officer, director or promoter · active 2012–2019 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Thermalin Diabetes, LLC | — | Biotechnology | Series A | $19.5M | $240.6M | 2012 |
| Deep Lens, Inc. | — | Other Technology | Series A | $16.8M | $378.8M | 2018 |
Jeffrey Elton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Elton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Shary | 1 | 11 |
| John Brooks | 1 | 8 |
| Michael Weiss | 1 | 8 |
| Richard Berenson | 1 | 4 |
| Raymond Rackley | 1 | 3 |
| Simon Arkell | 1 | 3 |
| Steven Tregay | 1 | 2 |
| Gerald Wisler | 1 | 2 |
| Joseph Jankowski | 1 | 1 |
| Dave Billiter | 1 | 1 |
| Bruce H. Frank | 1 | 1 |
| Tim Bowen | 1 | 1 |
| Mitchell Briskin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.